Top 20 Clinical-Stage Biopharmaceutical Companies - 2022
Governments, payers and consumers continue to place pressure on drug prices across the globe. In the U.S., pharmacy benefit managers (PBMs) and payers are negotiating more significant discounts, with declining net prices. Payers also are continuing to restrict coverage of therapies they deem too expensive; the Centers for Medicare & Medicaid Services’ (CMS) recent proposed coverage restriction of Aduhelm to clinical trial patients is just one example. Pricing pressure may also come from new competitors within the industry.
EQRx, the first of a potential wave of companies with disruptive “low-cost, me-too” strategies, intends to price its therapies 50-70 percent lower than competitors’ pricing. It has assembled a pipeline of at least five clinical assets and has partnerships or memoranda of understanding (MOUs) with CVS Health, Geisinger, Blue Shield of California, BlueCross BlueShield of North Carolina, Horizon and NHS England. The timing of its first filings remains to be seen, as their current pivotal trial data for two lead assets is from Chinese studies and U.S.- based studies are planned to begin this year. Additionally, the biosimilar pipeline is accelerating and may soon provide increased competition to numerous blockbuster franchises.
The Biden administration has set forth numerous proposed policies to control drug prices, such as Medicare drug price negotiation, penalties for price increases over inflation rates, earlier generic and biosimilar competition, and rebate transparency. Some of these provisions are included in the latest Build Back Better bill, though congressional gridlock makes it unclear whether and in what form they could be approved. Despite this, bipartisan pressure still exists for drug pricing reform, and smaller-scale changes in some form still could be imminent.
Combined, these trends are leading to fundamental shifts across the healthcare ecosystem. To win in this evolving landscape, industry leaders will have to monitor these trends and adapt their corporate strategies to make decisions regarding portfolio investments, new product launch strategies, capital formation and partnerships with industry participants.
We present to you, “Top 20 Clinical- Stage Biopharmaceutical Companies – 2022.”
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Clinical-Stage Biopharmaceutical Companies
